Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178078 | 0.89 | CTSL (0.41) | KMT2AMEN1TSHRALDH1A1CTSL | |
| SCHEMBL4183297 | 0.88 | CCR1 (0.50) | KMT2AMEN1ALDH1A1CTSLCTSS | |
| SCHEMBL4182029 | 0.88 | KMT2A (0.47) | KMT2AMEN1GAATSHRALDH1A1 | |
| SCHEMBL4186154 | 0.83 | CTSS (0.42) | ALDH1A1CTSLCTSSCTSKUTS2R | |
| SCHEMBL5488368 | 0.82 | CTSL (0.43) | KMT2AMEN1GAATSHRALDH1A1 | |
| SCHEMBL4178416 | 0.82 | UTS2R (0.51) | KMT2AMEN1CTSSCTSKUTS2R | |
| SCHEMBL5487944 | 0.81 | KMT2A (0.48) | KMT2AMEN1GAATSHRALDH1A1 | |
| SCHEMBL4178660 | 0.80 | SMN1; SMN2 (0.40) | KMT2AMEN1GAATSHRALDH1A1 | |
| SCHEMBL4191798 | 0.79 | CCR1 (0.51) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL4183423 | 0.78 | KMT2A (0.46) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | claimed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | KMT2A 3870/4885MEN1 3090/4885GAA 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.